Related Experiment Video

Updated: Jan 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

High-Risk Prostate Cancer in a Patient with Untreated Prolactinoma and Castrate-Level Testosterone Suppression: A

Tara A Seibert1, Afreen Shariff2,3, Hannah D McManus4,5

  • 1Department of Medicine, Duke University Hospital, Durham, NC, USA.

Case Reports in Oncology
|December 1, 2025
PubMed
Summary

Patients with prolactinomas, which cause low testosterone, can still develop prostate cancer (PCa). Careful treatment selection is crucial to manage hormonal interactions and avoid complications like pituitary apoplexy.

Keywords:
Androgen deprivation therapyHypogonadismPituitary apoplexyProlactinomaProstate cancer

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

637
Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.4K

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K